Verrica Pharmaceuticals Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Verrica Pharmaceuticals Inc. (VRCA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 8.34 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 6.76M shares, a 10.95% increase year-over-year.
- Verrica Pharmaceuticals Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 6.09M shares, a 23.53% decline year-over-year.
- Verrica Pharmaceuticals Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 7.97M shares, a 36.29% increase year-over-year.
- Verrica Pharmaceuticals Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 5.85M shares, a 39.37% increase year-over-year.
- Verrica Pharmaceuticals Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 6.79M shares, a 18.87% increase from fiscal 2024.
- Verrica Pharmaceuticals Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 5.72M shares, a 13.99% decline from fiscal 2023.
- Verrica Pharmaceuticals Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 6.65M shares, a 52.50% increase from fiscal 2022.
- Verrica Pharmaceuticals Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 4.36M shares, a 12.64% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 8.34M shares 10-Q · filed 2026-08-06 | |||||||
| 2026-03-31 | 6.76M shares 10-Q · filed 2026-05-12 | |||||||
| 2025-12-31 | 6.79M shares 10-K · filed 2026-03-11 | |||||||
| 2025-09-30 | 5.91M shares 10-Q · filed 2025-11-14 | |||||||
| 2025-06-30 | 5.97M shares 10-Q · filed 2026-08-06 | |||||||
| 2025-03-31 | 6.09M shares 10-Q · filed 2026-05-12 | 60.92M shares 10-Q · filed 2025-05-13 | ||||||
| 2024-12-31 | 5.72M shares 10-K · filed 2026-03-11 | 57.16M shares 10-K · filed 2025-03-11 | ||||||
| 2024-09-30 | 768.07K shares 10-Q · filed 2025-11-14 | 7.68M shares 10-Q · filed 2024-11-05 | ||||||
| 2024-06-30 | 850.91K shares 10-Q · filed 2025-08-12 | 8.51M shares 10-Q · filed 2024-08-14 | ||||||
| 2024-03-31 | 7.97M shares 10-Q · filed 2025-05-13 | |||||||
| 2023-12-31 | 6.65M shares 10-K · filed 2025-03-11 | |||||||
| 2023-09-30 | 6.06M shares 10-Q · filed 2024-11-05 | 6.58M shares 10-Q · filed 2023-11-09 | ||||||
| 2023-06-30 | 6.22M shares 10-Q · filed 2024-08-14 | |||||||
| 2023-03-31 | 5.85M shares 10-Q · filed 2024-05-13 | |||||||
| 2022-12-31 | 4.36M shares 10-K · filed 2024-02-29 | |||||||
| 2022-09-30 | 4.25M shares 10-Q · filed 2023-11-09 | |||||||
| 2022-06-30 | 3.86M shares 10-Q · filed 2023-08-08 | |||||||
| 2022-03-31 | 4.19M shares 10-Q · filed 2023-05-09 | |||||||
| 2021-12-31 | 3.87M shares 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |